Business Context and Reporting Period
The filing is Aeglea BioTherapeutics, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2020, filed November 5, 2020. The request identifies Spyre Therapeutics, Inc., but the provided filing identifies the registrant as Aeglea BioTherapeutics, Inc. Aeglea was a clinical-stage biotechnology company developing engineered human enzyme therapeutics for rare and high-burden diseases.
- Lead candidate: pegzilarginase for Arginase 1 Deficiency, evaluated in the global Phase 3 PEACE trial and a Phase 2 open-label extension study.
- ACN00177: Phase 1/2 development program for Homocystinuria.
- AEB5100: preclinical program for Cystinuria.
- The company had no product revenue and had not achieved profitable operations.
Financial Highlights
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $12.5 million vs. $17.8 million | $43.9 million vs. $47.0 million |
| General and administrative expense | $5.7 million vs. $4.3 million | $14.8 million vs. $11.4 million |
| Total operating expenses | $18.1 million vs. $22.1 million | $58.7 million vs. $58.4 million |
| Net loss | $18.0 million vs. $21.6 million | $58.2 million vs. $56.8 million |
| Net loss per share | $0.29 vs. $0.66 | $1.18 vs. $1.80 |
| Operating cash flow | Not separately provided | $(58.6) million vs. $(49.4) million |
Loss per share benefited from a substantially higher weighted-average share count, which increased to 62.2 million in the quarter and 49.5 million for the nine-month period, compared with 32.9 million and 31.6 million, respectively, in the prior-year periods.
Balance Sheet, Liquidity and Capitalization
- Cash and cash equivalents were $54.2 million at September 30, 2020, compared with $19.3 million at December 31, 2019.
- Marketable securities were $85.8 million, compared with $52.7 million at year-end 2019.
- Cash, cash equivalents, marketable securities and restricted cash totaled $141.5 million.
- Working capital was approximately $130.0 million.
- Total liabilities were $19.4 million and total stockholders’ equity was $136.3 million.
- The company reported no debt or credit facility and had $8.5 million of operating and finance lease commitments.
- In April 2020, the company raised approximately $129.0 million of net proceeds through an underwritten offering of common stock and pre-funded warrants.
- Between October 1 and November 4, 2020, it sold 3.25 million shares under an ATM program for approximately $24.6 million of net proceeds.
- Management stated that available resources, including the subsequent ATM proceeds, were expected to fund operations into 2023, although additional financing would be required to complete all planned development activities.
Material Changes Versus the Prior Comparable Period
- Third-quarter research and development expense decreased 30%, primarily because certain pegzilarginase manufacturing and pre-commercial activities, the pegzilarginase Phase 1/2 trial, cancer-related trials and supporting toxicology studies were completed. These savings were partly offset by higher personnel costs and Homocystinuria manufacturing activity.
- Nine-month research and development expense decreased 7%, as lower clinical and nonclinical development costs were partly offset by increased manufacturing and personnel costs.
- General and administrative expense increased 32% for the quarter and 30% for the nine-month period, reflecting expanded commercial capabilities, compensation and office space. Stock-based compensation was a contributing factor.
- Net loss increased 3% for the nine-month period despite relatively stable operating expenses, primarily because interest income declined as investment yields decreased.
- Operating cash use increased by $9.2 million year over year, while investing cash use increased by $24.2 million, largely reflecting purchases of marketable securities and property and equipment.
- Shares outstanding increased materially due to the April public offering and remained subject to dilution from 17.6 million outstanding pre-funded warrants.
Guidance, Outlook, Risks and Unusual Items
- Management expected to complete enrollment in the Phase 3 PEACE trial by January 2021 and to report topline data in mid-2021. The trial was approximately 70% enrolled as of November 5, 2020.
- COVID-19 temporarily suspended screening at PEACE trial sites, delayed enrollment and caused some missed dosing appointments. The company warned that further delays, protocol amendments, supply interruptions or data-quality issues could materially affect the program.
- The ACN00177 Phase 1/2 trial had been initiated, but timing of first patient dosing depended on site-level decisions because of COVID-19 pressures on healthcare systems.
- The company reported no significant supply-chain impact as of the filing date and believed it had sufficient clinical supply for ongoing trials.
- Key risks include failure of clinical trials, patient enrollment delays, adverse events, regulatory rejection or delay, reliance on third-party manufacturers and CROs, intellectual-property challenges, competition, reimbursement uncertainty and the need for additional capital.
- The company had accumulated losses of $253.3 million and expected continuing operating losses for the foreseeable future.
- The University of Texas license agreements could require up to $6.4 million in development and regulatory milestone payments, plus low-single-digit royalties and sublicense revenue sharing.
- The 228,200 performance-based restricted stock units granted in July 2020 could result in up to $1.9 million of future stock-based compensation if the specified milestones become probable.
- No material legal proceedings were reported, and management concluded that disclosure controls and procedures were effective at the reasonable-assurance level.
Investor Verification Checklist
- Confirm the registrant identity: the provided filing is for Aeglea BioTherapeutics, Inc., not Spyre Therapeutics, Inc.
- Verify PEACE trial enrollment, topline data timing and the effects of COVID-19 on trial integrity and regulatory timelines.
- Assess whether the stated liquidity runway into 2023 remains adequate under current development and commercialization spending assumptions.
- Review future financing needs, ATM capacity, public offering history and dilution from outstanding pre-funded warrants.
- Evaluate clinical efficacy, safety and regulatory risks for pegzilarginase and ACN00177, including the potential for additional trials or clinical holds.
- Review dependence on third-party manufacturers and CROs, including supply concentration and business-continuity risks.
- Monitor milestone obligations, royalties and revenue-sharing requirements under the University of Texas license.